Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Mar 12;458(7235):206-10.
doi: 10.1038/nature07662. Epub 2008 Dec 10.

Enhancing SIV-specific immunity in vivo by PD-1 blockade

Vijayakumar Velu  1 , Kehmia Titanji, Baogong Zhu, Sajid Husain, Annette Pladevega, Lilin Lai, Thomas H Vanderford, Lakshmi Chennareddi, Guido Silvestri, Gordon J Freeman, Rafi Ahmed, Rama Rao Amara
Affiliations

Enhancing SIV-specific immunity in vivo by PD-1 blockade

Vijayakumar Velu et al. Nature. .

Abstract

Chronic immunodeficiency virus infections are characterized by dysfunctional cellular and humoral antiviral immune responses. As such, immune modulatory therapies that enhance and/or restore the function of virus-specific immunity may protect from disease progression. Here we investigate the safety and immune restoration potential of blockade of the co-inhibitory receptor programmed death 1 (PD-1) during chronic simian immunodeficiency virus (SIV) infection in macaques. We demonstrate that PD-1 blockade using an antibody to PD-1 is well tolerated and results in rapid expansion of virus-specific CD8 T cells with improved functional quality. This enhanced T-cell immunity was seen in the blood and also in the gut, a major reservoir of SIV infection. PD-1 blockade also resulted in proliferation of memory B cells and increases in SIV envelope-specific antibody. These improved immune responses were associated with significant reductions in plasma viral load and also prolonged the survival of SIV-infected macaques. Blockade was effective during the early (week 10) as well as late ( approximately week 90) phases of chronic infection even under conditions of severe lymphopenia. These results demonstrate enhancement of both cellular and humoral immune responses during a pathogenic immunodeficiency virus infection by blocking a single inhibitory pathway and identify a novel therapeutic approach for control of human immunodeficiency virus infections.

PubMed Disclaimer

Figures

Figure 1
Figure 1. In vivo PD-1 blockade during chronic SIV infection increases the Gag CM9-specific CD8 T cells with improved functional quality in both blood and gut
a) Representative FACS plots for the macaque RRk10. The magnitude and phenotype of Gag CM9-tetramer positive CD8 T cells in blood (b) and gut (colorectal mucosal tissue) (c). Representative FACS plots are shown on the left and summary for all Mamu A*01 positive animals is shown on the right. Numbers on the FACS plots represent the frequency of tetramer positive cells as a percent of total CD8 T cells. Arrows and vertical dotted lines indicate anti-PD-1 Ab or control Ab treatment.
Figure 2
Figure 2. In vivo PD-1 blockade during chronic SIV infection increases the polyfunctional virus-specific CD8 T cells
a) Frequency of Gag-specific cytokine secreting CD8 T cells as a percent of total CD8 T cells. Representative FACS plots are shown on the left and summary for the group is shown on the right. Arrows and vertical dotted lines indicate anti-PD-1 Ab or control Ab treatment. Green lines represent anti-PD-1 Ab treated macaques and red lines represent control Ab treated macaques. b) Cytokine co-expression subsets expressed as a percent of total cytokine positive cells. Mean for the group is shown.
Figure 3
Figure 3. In vivo PD-1 blockade during chronic SIV infection enhances SIV-specific humoral immunity
a) Expression of PD-1 on memory (CD20+CD27+CD21-) and naïve (CD20+CD27-CD21+) B cells in blood following SIV infection and prior to in vivo PD-1 blockade. b) Titers of anti-SIV Env binding Ab in serum following blockade. c) Ki-67 expression (marker for proliferation) on memory and naïve B cells following blockade. Numbers on the FACS plots represent Ki-67 positive cells as a percent of respective total cells. Macaques RAf11 and RJd11 were treated simultaneously with anti-PD-1 Ab and anti-retroviral therapy at 22 weeks post SIV infection.
Figure 4
Figure 4. In vivo PD-1 blockade reduces plasma viremia and prolongs survival of SIV-infected macaques
Plasma viral load in a) macaques treated with anti-PD-1 Ab during the early chronic phase b) macaques treated with anti-PD-1 Ab during the late chronic phase and c) macaques treated with control Ab during the early/late chronic phase of SIV infection. d) Fold reduction in plasma viral load between day 0 and day 28 (early chronic study) or day 0 and day 21 (late chronic study). e) Survival of SIV-infected macaques following PD-1 blockade. =, death of animal.
None
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wherry EJ, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007;27:670–684. - PubMed
    1. Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol. 2005;6:873–879. - PubMed
    1. Zajac AJ, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998;188:2205–2213. see comments. - PMC - PubMed
    1. Gallimore A, et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med. 1998;187:1383–1393. - PMC - PubMed
    1. Letvin NL, Walker BD. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med. 2003;9:861–866. - PubMed

Publication types

MeSH terms

Associated data